• Determine the antiviral effect of TMC435 during 7 days once daily dosing at 200mg orally (by mouth) as monotherapy in treatment naÃ-ve, genotype 2 to 6 HCV-infected patients.
  

• Determine the safety, tolerability and PK profile of TMC435 during 7 days once daily dosing at 200mg as monotherapy in treatment naÃ-ve, genotype 2 to 6 HCV-infected patients.
  

This is an open-label, phase IIa study to assess the activity of TMC435 in patients who have been infected with the hepatitis C virus (HCV) for a long time and who have never been treated for their hepatits C infection. The study consists of a screening period of maximum 6 weeks, a treatment period of 7 days and a follow-up period of 4 weeks. A total of 40 HCV-infected patients who have never been treated for HCV (8 patients per HCV genotype) will be enrolled in the study. All patients will receive TMC435 200mg once daily orally (by mounth) for 7 days. Subsequently, they can continue with Standard of Care (SoC) treatment consisting of pegylated interferon and ribavirin upon agreement with the study doctor. The SoC will be given outside the scope of this study. The primary outcome in the study is to determine the antiviral effect of TMC435 when administered as monotherapy to treatment naïve, genotype 2 to 6 HCV-infected patients at a daily dose of 200mg orally (by mouth) for 7 days. During the treatment period, all patients will be assessed on a daily basis until 4 days following the last intake of TMC435. HCV viral load quantification and safety / tolerability assessments will be performed. Virologic and pharmacokinetic (PK) assessments for pharmacokinetic / pharmacodynamic analyses will be performed during the investigational treatment period.

TMC435 200 mg once daily orally (by mouth) for 7 days as monotherapy